Precision Medicine in Oncology®

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

The European Commission has approved alectinib for adjuvant use in adult patients with ALK+ non–small cell lung cancer at high risk of recurrence.

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

Here is your guide to important regulatory approvals made by the FDA in May 2024.

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Arianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.